A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome

Nicole P. Bowles, Ilia N. Karatsoreos, Xiaosong Li, V. Kiran Vemuri, Jodi Anne Wood, Zhiying Li, Kellie L K Tamashiro, Gary J. Schwartz, Alexandros M. Makriyannis, George Kunos, Cecilia J. Hillard, Bruce S. McEwen, Matthew N. Hill

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Glucocorticoids are known to promote the development of metabolic syndrome through the modulation of both feeding pathways and metabolic processes; however, the precise mechanisms of these effects are not well-understood. Recent evidence shows that glucocorticoids possess the ability to increase endocannabinoid signaling, which is known to regulate appetite, energy balance, and metabolic processes through both central and peripheral pathways. The aim of this study was to determine the role of endocannabinoid signaling in glucocorticoid-mediated obesity and metabolic syndrome. Using a mouse model of excess corticosterone exposure, we found that the ability of glucocorticoids to increase adiposity, weight gain, hormonal dysregulation, hepatic steatosis, and dyslipidemia was reduced or reversed in mice lacking the cannabinoid CB1 receptor as well as mice treated with the global CB1 receptor antagonist AM251. Similarly, a neutral, peripherally restricted CB1 receptor antagonist (AM6545) was able to attenuate the metabolic phenotype caused by chronic corticosterone, suggesting a peripheral mechanism for these effects. Biochemical analyses showed that chronic excess glucocorticoid exposure produced a significant increase in hepatic and circulating levels of the endocannabinoid anandamide, whereas no effect was observed in the hypothalamus. To test the role of the liver, specific and exclusive deletion of hepatic CB1 receptor resulted in a rescue of the dyslipidemic effects of glucocorticoid exposure, while not affecting the obesity phenotype or the elevations in insulin and leptin. Together, these data indicate that glucocorticoids recruit peripheral endocannabinoid signaling to promote metabolic dysregulation, with hepatic endocannabinoid signaling being especially important for changes in lipid metabolism.

Original languageEnglish (US)
Pages (from-to)285-290
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume112
Issue number1
DOIs
StatePublished - Jan 6 2015

Fingerprint

Endocannabinoids
Glucocorticoids
Cannabinoid Receptor CB1
Liver
Aptitude
Corticosterone
Obesity
Phenotype
Adiposity
Appetite
Dyslipidemias
Leptin
Lipid Metabolism
Hypothalamus
Weight Gain
Insulin

Keywords

  • 2-AG
  • Anandamide
  • Corticosterone
  • Liver
  • Obesity

ASJC Scopus subject areas

  • General

Cite this

A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. / Bowles, Nicole P.; Karatsoreos, Ilia N.; Li, Xiaosong; Vemuri, V. Kiran; Wood, Jodi Anne; Li, Zhiying; Tamashiro, Kellie L K; Schwartz, Gary J.; Makriyannis, Alexandros M.; Kunos, George; Hillard, Cecilia J.; McEwen, Bruce S.; Hill, Matthew N.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 112, No. 1, 06.01.2015, p. 285-290.

Research output: Contribution to journalArticle

Bowles, NP, Karatsoreos, IN, Li, X, Vemuri, VK, Wood, JA, Li, Z, Tamashiro, KLK, Schwartz, GJ, Makriyannis, AM, Kunos, G, Hillard, CJ, McEwen, BS & Hill, MN 2015, 'A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome', Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 1, pp. 285-290. https://doi.org/10.1073/pnas.1421420112
Bowles, Nicole P. ; Karatsoreos, Ilia N. ; Li, Xiaosong ; Vemuri, V. Kiran ; Wood, Jodi Anne ; Li, Zhiying ; Tamashiro, Kellie L K ; Schwartz, Gary J. ; Makriyannis, Alexandros M. ; Kunos, George ; Hillard, Cecilia J. ; McEwen, Bruce S. ; Hill, Matthew N. / A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. In: Proceedings of the National Academy of Sciences of the United States of America. 2015 ; Vol. 112, No. 1. pp. 285-290.
@article{c822a23021b54f019aedf6fad4df0a27,
title = "A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome",
abstract = "Glucocorticoids are known to promote the development of metabolic syndrome through the modulation of both feeding pathways and metabolic processes; however, the precise mechanisms of these effects are not well-understood. Recent evidence shows that glucocorticoids possess the ability to increase endocannabinoid signaling, which is known to regulate appetite, energy balance, and metabolic processes through both central and peripheral pathways. The aim of this study was to determine the role of endocannabinoid signaling in glucocorticoid-mediated obesity and metabolic syndrome. Using a mouse model of excess corticosterone exposure, we found that the ability of glucocorticoids to increase adiposity, weight gain, hormonal dysregulation, hepatic steatosis, and dyslipidemia was reduced or reversed in mice lacking the cannabinoid CB1 receptor as well as mice treated with the global CB1 receptor antagonist AM251. Similarly, a neutral, peripherally restricted CB1 receptor antagonist (AM6545) was able to attenuate the metabolic phenotype caused by chronic corticosterone, suggesting a peripheral mechanism for these effects. Biochemical analyses showed that chronic excess glucocorticoid exposure produced a significant increase in hepatic and circulating levels of the endocannabinoid anandamide, whereas no effect was observed in the hypothalamus. To test the role of the liver, specific and exclusive deletion of hepatic CB1 receptor resulted in a rescue of the dyslipidemic effects of glucocorticoid exposure, while not affecting the obesity phenotype or the elevations in insulin and leptin. Together, these data indicate that glucocorticoids recruit peripheral endocannabinoid signaling to promote metabolic dysregulation, with hepatic endocannabinoid signaling being especially important for changes in lipid metabolism.",
keywords = "2-AG, Anandamide, Corticosterone, Liver, Obesity",
author = "Bowles, {Nicole P.} and Karatsoreos, {Ilia N.} and Xiaosong Li and Vemuri, {V. Kiran} and Wood, {Jodi Anne} and Zhiying Li and Tamashiro, {Kellie L K} and Schwartz, {Gary J.} and Makriyannis, {Alexandros M.} and George Kunos and Hillard, {Cecilia J.} and McEwen, {Bruce S.} and Hill, {Matthew N.}",
year = "2015",
month = "1",
day = "6",
doi = "10.1073/pnas.1421420112",
language = "English (US)",
volume = "112",
pages = "285--290",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "1",

}

TY - JOUR

T1 - A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome

AU - Bowles, Nicole P.

AU - Karatsoreos, Ilia N.

AU - Li, Xiaosong

AU - Vemuri, V. Kiran

AU - Wood, Jodi Anne

AU - Li, Zhiying

AU - Tamashiro, Kellie L K

AU - Schwartz, Gary J.

AU - Makriyannis, Alexandros M.

AU - Kunos, George

AU - Hillard, Cecilia J.

AU - McEwen, Bruce S.

AU - Hill, Matthew N.

PY - 2015/1/6

Y1 - 2015/1/6

N2 - Glucocorticoids are known to promote the development of metabolic syndrome through the modulation of both feeding pathways and metabolic processes; however, the precise mechanisms of these effects are not well-understood. Recent evidence shows that glucocorticoids possess the ability to increase endocannabinoid signaling, which is known to regulate appetite, energy balance, and metabolic processes through both central and peripheral pathways. The aim of this study was to determine the role of endocannabinoid signaling in glucocorticoid-mediated obesity and metabolic syndrome. Using a mouse model of excess corticosterone exposure, we found that the ability of glucocorticoids to increase adiposity, weight gain, hormonal dysregulation, hepatic steatosis, and dyslipidemia was reduced or reversed in mice lacking the cannabinoid CB1 receptor as well as mice treated with the global CB1 receptor antagonist AM251. Similarly, a neutral, peripherally restricted CB1 receptor antagonist (AM6545) was able to attenuate the metabolic phenotype caused by chronic corticosterone, suggesting a peripheral mechanism for these effects. Biochemical analyses showed that chronic excess glucocorticoid exposure produced a significant increase in hepatic and circulating levels of the endocannabinoid anandamide, whereas no effect was observed in the hypothalamus. To test the role of the liver, specific and exclusive deletion of hepatic CB1 receptor resulted in a rescue of the dyslipidemic effects of glucocorticoid exposure, while not affecting the obesity phenotype or the elevations in insulin and leptin. Together, these data indicate that glucocorticoids recruit peripheral endocannabinoid signaling to promote metabolic dysregulation, with hepatic endocannabinoid signaling being especially important for changes in lipid metabolism.

AB - Glucocorticoids are known to promote the development of metabolic syndrome through the modulation of both feeding pathways and metabolic processes; however, the precise mechanisms of these effects are not well-understood. Recent evidence shows that glucocorticoids possess the ability to increase endocannabinoid signaling, which is known to regulate appetite, energy balance, and metabolic processes through both central and peripheral pathways. The aim of this study was to determine the role of endocannabinoid signaling in glucocorticoid-mediated obesity and metabolic syndrome. Using a mouse model of excess corticosterone exposure, we found that the ability of glucocorticoids to increase adiposity, weight gain, hormonal dysregulation, hepatic steatosis, and dyslipidemia was reduced or reversed in mice lacking the cannabinoid CB1 receptor as well as mice treated with the global CB1 receptor antagonist AM251. Similarly, a neutral, peripherally restricted CB1 receptor antagonist (AM6545) was able to attenuate the metabolic phenotype caused by chronic corticosterone, suggesting a peripheral mechanism for these effects. Biochemical analyses showed that chronic excess glucocorticoid exposure produced a significant increase in hepatic and circulating levels of the endocannabinoid anandamide, whereas no effect was observed in the hypothalamus. To test the role of the liver, specific and exclusive deletion of hepatic CB1 receptor resulted in a rescue of the dyslipidemic effects of glucocorticoid exposure, while not affecting the obesity phenotype or the elevations in insulin and leptin. Together, these data indicate that glucocorticoids recruit peripheral endocannabinoid signaling to promote metabolic dysregulation, with hepatic endocannabinoid signaling being especially important for changes in lipid metabolism.

KW - 2-AG

KW - Anandamide

KW - Corticosterone

KW - Liver

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=84920450557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920450557&partnerID=8YFLogxK

U2 - 10.1073/pnas.1421420112

DO - 10.1073/pnas.1421420112

M3 - Article

C2 - 25535367

AN - SCOPUS:84920450557

VL - 112

SP - 285

EP - 290

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 1

ER -